Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses

Vaccines (Basel). 2021 Oct 22;9(11):1230. doi: 10.3390/vaccines9111230.


Vector-borne flaviviruses are responsible for nearly half a billion human infections worldwide each year, resulting in millions of cases of debilitating and severe diseases and approximately 115,000 deaths. While approved vaccines are available for some of these viruses, the ongoing efficacy, safety and supply of these vaccines are still a significant problem. New technologies that address these issues and ideally allow for the safe and economical manufacture of vaccines in resource-poor countries where flavivirus vaccines are in most demand are urgently required. Preferably a new vaccine platform would be broadly applicable to all flavivirus diseases and provide new candidate vaccines for those diseases not yet covered, as well as the flexibility to rapidly pivot to respond to newly emerged flavivirus diseases. Here, we review studies conducted on novel chimeric vaccines derived from insect-specific flaviviruses that provide a potentially safe and simple system to produce highly effective vaccines against a broad spectrum of flavivirus diseases.

Keywords: Binjari virus; Japanese encephalitis; West Nile virus disease; Zika; chimeric virus; dengue; flavivirus; insect-specific flavivirus; vaccine platform; yellow fever.

Publication types

  • Review